Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia

Eddy Fadlyana; Djatnika Setiabudi; C B Kartasasmita; Nina Dwi Putri; Sri Rezeki Hadinegoro; Kim Mulholland; Yulia Sofiatin; Hendarsyah Suryadinata; Yovita Hartantri; Hadyana Sukandar; Agnes Rengga Indrati; Chrysanti Murad; Vivi Setiawaty; Krisna Nur Andriana Pangesti; Pretty Multihartina; Citra Vravita Khrisna; Masayu Riela Ayuninda; Pratama Wicaksana; Aqila Sakina Zhafira; Robert Sinto; Kusnandi Rusmil; Julitasari Sundoro; Emma Watts; Cattram Nguyen

The Lancet Infectious Diseases (2023) - Comments
doi: 10.1016/s1473-3099(22)00800-3 issn: 1473-3099 pubmed: 36640798

Eddy Fadlyana, Djatnika Setiabudi, C B Kartasasmita, Nina Dwi Putri, Sri Rezeki Hadinegoro, Kim Mulholland, Yulia Sofiatin, Hendarsyah Suryadinata, Yovita Hartantri, Hadyana Sukandar, Agnes Rengga Indrati, Chrysanti Murad, Vivi Setiawaty, Krisna Nur Andriana Pangesti, Pretty Multihartina, Citra Vravita Khrisna, Masayu Riela Ayuninda, Pratama Wicaksana, Aqila Sakina Zhafira, Robert Sinto